By Colin Kellaher
Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.
Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile.
The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension.
Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 10, 2025 07:19 ET (11:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。